TCL Archive DCT Board Approves Three New BRMP RFAs For Immunologic Research, $1.5 Million A Year February 27, 1987
TCL Archive Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease December 28, 2012
TCL Archive Did ACS Flip-Flop On Stem Cell Research? Society Says No, Patient Coalition Says Yes September 10, 1999
TCL Archive Science Policy: Increased Cancer Death Rate For Atomic Vets Not Significant, OIM Says October 29, 1999
